NewsBenzingaImmuCell: utile per azione del terzo trimestre di $0,10, in aumento rispetto a $(0,02) su base annua; vendite a $8,040 milioni, in aumento rispetto a $5,506 milioni su base annua. ImmuCell: utile per azione del terzo trimestre di $0,10, in aumento rispetto a $(0,02) su base annua; vendite a $8,040 milioni, in aumento rispetto a $5,506 milioni su base annua. Benzinga 2026.11.12 21:15 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story